Golusiński Paweł, Pazdrowski Jakub, Szewczyk Mateusz, Misiołek Maciej, Pietruszewska Wioletta, Klatka Janusz, Okła Sławomir, Kaźmierczak Henryk, Marszałek Andrzej, Filas Violetta, Schneider Augusto, Masternak Michał M, Stęplewska Katarzyna, Miśkiewicz-Orczyk Katarzyna, Golusiński Wojciech
Department of Head and Neck Surgery, Poznan University of Medical Sciences, Greater Poland Cancer Centre, Poznan, Poland.
Department of Biology and Environmental Studies, Poznan University of Medical Sciences, Poznan, Poland.
Rep Pract Oncol Radiother. 2017 May-Jun;22(3):237-242. doi: 10.1016/j.rpor.2017.01.003. Epub 2017 Apr 22.
Our goal was to determine the expression levels of p16 in the cohort of the OPSCC patients and evaluation of the pathological and clinical differences between these two groups including patients' survival.
HPV infection is the main causative factor of oropharyngeal cancer (OPSCC). Identification of HPV status in OPSCC requires positive evaluation of viral DNA integration into host cell however, p16 accumulation in the proliferating cell layers has been accepted as an alternative marker for HPV infection.
The IHC staining for p16 has been performed in tumor tissue from 382 OPSCC patients. The sample was considered positive based on more than 70% of carcinoma tissue showing strong and diffused nuclear and cytoplasmic immunostaining. The clinicopathological characteristics of the patients including site, age, gender, tumor grade, tumor stage, the nodal status, smoking and survival have been analyzed when comparing p16 positive and p16 negative tumors.
Out of our cohort in 38.2% cases positive staining for p16 has been recorded. Our analysis did not indicate significant differences in the distribution of the p16 positive patients and age of the patients, stage of the disease. Among the patients who have presented with the N+ neck, there were significantly more p16 positive tumors than in the group with N0 neck ( = 0.0062). There was highly significant correlation between the expression of p16 and smoking ( < 0.0001). The significant difference in survival ( < 0.0001) with more favorable prognosis in the p16 positive group has been observed.
Overexpression of p16 is accepted as a surrogate diagnostic marker for detecting HPV infection in oropharyngeal cancer. However, one should remember about existence of the small subgroups of p16 positive but HPV negative tumors, with relatively worse prognosis. Immunostaining for p16, however useful on everyday basis, should be complemented with other techniques in terms of reliable identification of the HPV infection.
我们的目标是确定口咽鳞状细胞癌（OPSCC）患者队列中p16的表达水平，并评估这两组患者之间的病理和临床差异，包括患者的生存率。
人乳头瘤病毒（HPV）感染是口咽癌（OPSCC）的主要致病因素。确定OPSCC中的HPV状态需要对病毒DNA整合到宿主细胞中进行阳性评估，然而，增殖细胞层中p16的积累已被视为HPV感染的替代标志物。
对382例OPSCC患者的肿瘤组织进行了p16的免疫组化染色。如果超过70%的癌组织显示强烈且弥漫的核和细胞质免疫染色，则该样本被视为阳性。在比较p16阳性和p16阴性肿瘤时，分析了患者的临床病理特征，包括部位、年龄、性别、肿瘤分级、肿瘤分期、淋巴结状态、吸烟情况和生存率。
在我们的队列中，38.2%的病例记录为p16染色阳性。我们的分析未表明p16阳性患者的分布、患者年龄和疾病分期存在显著差异。在出现颈部淋巴结转移（N+）的患者中，p16阳性肿瘤明显多于无颈部淋巴结转移（N0）的组（P = 0.0062）。p16的表达与吸烟之间存在高度显著相关性（P < 0.0001）。观察到生存率存在显著差异（P < 0.0001），p16阳性组的预后更有利。
p16的过表达被认为是检测口咽癌中HPV感染的替代诊断标志物。然而，应该记住存在一小部分p16阳性但HPV阴性的肿瘤亚组，其预后相对较差。尽管p16免疫染色在日常工作中很有用，但在可靠鉴定HPV感染方面，应辅以其他技术。
